Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
European Journal of Haematology|July 5, 2017
Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapiesFlora Zagouri, Efstathios Kastritis, Athanasios Zomas, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|September 28, 2017
Protein Z (PZ) and plasminogen activator inhibitor-1 (PAI-1) plasma levels in patients with previously untreated Hodgkin lymphoma (HL)Georgios Boutsikas, Evangelos Terpos, Athanasios Markopoulos, et al.
Anticancer Research|October 7, 2017
The Significance of PET/CT in the Initial Staging of Hodgkin Lymphoma: Experience Outside Clinical TrialsMaria K Angelopoulou, Eftychia Mosa, Gerassimos A Pangalis, et al.
The Oncologist|February 28, 2016
Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent RegimensTheodoros P Vassilakopoulos, Maria N Dimopoulou, Maria K Angelopoulou, et al.
Hematological Oncology|February 14, 2021
Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomasMaria Dimou, Sotirios G Papageorgiou, Niki Stavroyianni, et al.
Cancers|January 23, 2024
Prognostic Impact of Serum β2-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 PatientsTheodoros P Vassilakopoulos, Maria Arapaki, Panagiotis T Diamantopoulos, et al.
Leukemia & Lymphoma|February 21, 2022
Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significanceStamatios Karakatsanis, Fotios Panitsas, Maria Arapaki, et al.
Annals of Hematology|February 1, 2021
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategiesTheodoros P Vassilakopoulos, Sotirios G Papageorgiou, Maria K Angelopoulou, et al.
The Oncologist|April 19, 2021
Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOPTheodoros P Vassilakopoulos, Michail Michail, Sotirios Papageorgiou, et al.
In Vivo (Athens, Greece)|April 28, 2022
Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell LymphomaStamatis J Karakatsanis, Maria Bouzani, Argyris Symeonidis, et al.
Pageof 6